Loading...
Phase I Trial of 17-Allylamino-17-Demethoxygeldanamycin in Patients with Advanced Cancer
PURPOSE: To define the maximum tolerated dose (MTD), toxicities, and pharmacokinetics of 17-allylamino-17-demethoxygeldanamycin (17-AAG) when administered using continuous and intermittent dosing schedules. EXPERIMENTAL DESIGN: Patients with progressive solid tumor malignancies were treated with 17-...
Na minha lista:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2007
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3203693/ https://ncbi.nlm.nih.gov/pubmed/17363532 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-06-1863 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|